237 related articles for article (PubMed ID: 36350986)
21. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8
Hermans D; Gautam S; García-Cañaveras JC; Gromer D; Mitra S; Spolski R; Li P; Christensen S; Nguyen R; Lin JX; Oh J; Du N; Veenbergen S; Fioravanti J; Ebina-Shibuya R; Bleck C; Neckers LM; Rabinowitz JD; Gattinoni L; Leonard WJ
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6047-6055. PubMed ID: 32123114
[TBL] [Abstract][Full Text] [Related]
22. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
23. Circ_0030586 inhibits cell proliferation and stemness in bladder cancer by inactivating the ERK signaling via miR-665/NR4A3 axis.
Fan L; Yang J; Shen C; Wu Z; Hu H
Acta Histochem; 2021 Jul; 123(5):151745. PubMed ID: 34175686
[TBL] [Abstract][Full Text] [Related]
24. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
Du X; Darcy PK; Wiede F; Tiganis T
Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
[TBL] [Abstract][Full Text] [Related]
25. Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.
Funk CR; Petersen CT; Jagirdar N; Ravindranathan S; Jaye DL; Flowers CR; Langston A; Waller EK
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30572564
[TBL] [Abstract][Full Text] [Related]
26. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
27. FOXO1 is a master regulator of memory programming in CAR T cells.
Doan AE; Mueller KP; Chen AY; Rouin GT; Chen Y; Daniel B; Lattin J; Markovska M; Mozarsky B; Arias-Umana J; Hapke R; Jung IY; Wang A; Xu P; Klysz D; Zuern G; Bashti M; Quinn PJ; Miao Z; Sandor K; Zhang W; Chen GM; Ryu F; Logun M; Hall J; Tan K; Grupp SA; McClory SE; Lareau CA; Fraietta JA; Sotillo E; Satpathy AT; Mackall CL; Weber EW
Nature; 2024 May; 629(8010):211-218. PubMed ID: 38600391
[TBL] [Abstract][Full Text] [Related]
28. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
[TBL] [Abstract][Full Text] [Related]
29. The Orphan Nuclear Receptor NR4A3 Is Involved in the Function of Dendritic Cells.
Nagaoka M; Yashiro T; Uchida Y; Ando T; Hara M; Arai H; Ogawa H; Okumura K; Kasakura K; Nishiyama C
J Immunol; 2017 Oct; 199(8):2958-2967. PubMed ID: 28893954
[TBL] [Abstract][Full Text] [Related]
30. High Levels of Eomes Promote Exhaustion of Anti-tumor CD8
Li J; He Y; Hao J; Ni L; Dong C
Front Immunol; 2018; 9():2981. PubMed ID: 30619337
[TBL] [Abstract][Full Text] [Related]
31. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
32.
Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
[TBL] [Abstract][Full Text] [Related]
33. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
35.
Sun C; Li D; Wang Z
Immunotherapy; 2024 Mar; 16(5):331-340. PubMed ID: 38264838
[TBL] [Abstract][Full Text] [Related]
36. Elevation of NR4A3 expression and its possible role in modulating insulin expression in the pancreatic beta cell.
Gao W; Fu Y; Yu C; Wang S; Zhang Y; Zong C; Xu T; Liu Y; Li X; Wang X
PLoS One; 2014; 9(3):e91462. PubMed ID: 24638142
[TBL] [Abstract][Full Text] [Related]
37. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells.
Zhang X; Zhang C; Qiao M; Cheng C; Tang N; Lu S; Sun W; Xu B; Cao Y; Wei X; Wang Y; Han W; Wang H
Cancer Cell; 2022 Nov; 40(11):1407-1422.e7. PubMed ID: 36240777
[TBL] [Abstract][Full Text] [Related]
38. FOXP1 and KLF2 reciprocally regulate checkpoints of stem-like to effector transition in CAR T cells.
Zhu Z; Lou G; Teng XL; Wang H; Luo Y; Shi W; Yihunie K; Hao S; DeGolier K; Liao C; Huang H; Zhang Q; Fry T; Wang T; Yao C; Wu T
Nat Immunol; 2024 Jan; 25(1):117-128. PubMed ID: 38012417
[TBL] [Abstract][Full Text] [Related]
39. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
[TBL] [Abstract][Full Text] [Related]
40. The CD39
Zou F; Tan J; Liu T; Liu B; Tang Y; Zhang H; Li J
Mol Ther; 2021 May; 29(5):1794-1807. PubMed ID: 33484968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
